Alzheimers & Dementia is a premier journal published by WILEY that focuses on the latest advancements in understanding, diagnosing, and treating Alzheimer's disease and other dementias. With an ISSN of 1552-5260 and an E-ISSN of 1552-5279, this influential journal boasts a commendable impact factor and ranks in the Q1 category across several disciplines, including *Cellular and Molecular Neuroscience*, *Geriatrics and Gerontology*, and *Neurology (Clinical)*. By publishing cutting-edge research, systematic reviews, and innovative clinical trials, Alzheimers & Dementia aims to bridge the gap between basic neuroscience and clinical practice, offering valuable insights into the etiology, epidemiology, and management of dementia-related disorders. The journal is hosted in the United States and operates under a balanced access model, providing essential resources for researchers, healthcare professionals, and students dedicated to tackling the challenges posed by these neurodegenerative diseases. Available online, it plays a pivotal role in shaping current and future research directions in the vibrant field of dementia studies.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, published by Lippincott Williams & Wilkins, is a pivotal journal for advancing knowledge in the fields of clinical psychology, geriatric medicine, and psychiatry. With a history spanning from 1987 to 2024, this journal provides a comprehensive platform for researchers and clinicians to disseminate significant findings related to Alzheimer's disease and associated cognitive disorders. Ranked within the second and third quartiles in various categories, including clinical psychology and geriatrics, it retains a solid academic reputation, indicated by its diverse Scopus rankings, such as #137 in Clinical Psychology and #20 in Nursing & Gerontology. Although it does not offer open access, the journal is recognized for its commitment to peer-reviewed research, making it a valuable resource for professionals and students alike, aiming to stay abreast of the latest developments and evidence-based practices in Alzheimer’s and associated conditions.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS is a distinguished peer-reviewed journal published by KARGER, based in Switzerland. With a focus on the critical fields of cognitive neuroscience, geriatrics, and psychiatry, this journal is integral to advancing our understanding of cognitive decline and geriatric health. Despite being established from 1990 through 1992 and relaunching its scope in 1994, it has consistently provided a platform for innovative research, as reflected in its strong impact factor and notable Scopus rankings, placing it in the Q2 quartile for disciplines including cognitive neuroscience and geriatric medicine. The journal aims to foster interdisciplinary dialogue and collaboration among researchers, healthcare professionals, and educators, contributing to the growing field of dementia research and elderly care. Open access options further ensure that this vital knowledge is widely accessible, making a significant impact in both academic and clinical settings. With a commitment to quality and relevance, DEMENTIA AND GERIATRIC COGNITIVE DISORDERS remains a key resource for those dedicated to understanding and addressing the challenges posed by cognitive disorders in aging populations.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

Current Alzheimer Research is a pivotal journal dedicated to advancing knowledge in the field of neurology, with a particular focus on Alzheimer's disease and related neurodegenerative disorders. Published by BENTHAM SCIENCE PUBL LTD, this journal contributes to the growing body of literature aimed at bridging the gap between clinical research and practical application. Operating out of the United Arab Emirates, it has established itself as a reputable source for interdisciplinary research and clinical studies, reflecting its category quartiles ranking of Q3 in both Neurology and Clinical Neurology as of 2023. The journal, which spans from 2004 to 2024, provides scientists, clinicians, and students with up-to-date research findings while fostering an environment of knowledge exchange. Researchers are encouraged to submit their work, share insights, and engage with the latest discoveries that aim to enhance understanding and treatment strategies in Alzheimer’s disease, thereby addressing one of the most pressing challenges in neuroscience today.

The JOURNAL OF AGING AND HEALTH, published by SAGE PUBLICATIONS INC, is a preeminent peer-reviewed journal dedicated to advancing research in the field of gerontology and related disciplines. With an impressive impact factor and ranked Q1 across multiple categories including Community and Home Care, Geriatrics and Gerontology, and Health (Social Science), this journal has established itself as a vital resource for academics, clinicians, and policymakers alike. Spanning over three decades of publication from 1989 to 2024, it serves as a platform for innovative research and multifaceted discussions on aging, health, and the interplay of social factors influencing the elderly population. The journal's rigorous standards for publication ensure high-quality contributions that are impactful and relevant, making it an essential read for those dedicated to improving the health and quality of life for older adults. Although it is not an open-access journal, it provides comprehensive insights that are critical to understanding the complexities of aging in today's society.

International Journal of Geriatric Psychiatry, published by Wiley, stands as a premier journal dedicated to advancing the field of mental health in older adults. With an impressive impact factor reflective of its Q1 categorization in both Geriatrics and Gerontology, as well as Psychiatry and Mental Health, this journal addresses the critical intersection of aging and mental health, providing a platform for impactful research from 1986 through 2024. Researchers and professionals will find the journal invaluable, as it offers comprehensive insights into a range of subjects pertinent to geriatric mental health, with its ranking in Scopus highlighting its academic rigor and relevance (Rank #147/567 in Psychiatry and Mental Health; Rank #37/116 in Geriatrics and Gerontology). Though it operates on a traditional subscription model, the journal's significant contributions to the understanding of psychiatric disorders in the elderly make it a key resource for anyone involved in geriatric care and research.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.